Vistagen Therapeutics (VTGN) Receivables (2011 - 2026)
Vistagen Therapeutics (VTGN) posted Receivables of $56000.0 for Q1 2026, down 24.32% sequentially from $74000.0 in Q4 2025, and down 56.92% YoY from $130000.0 in Q1 2025.
Vistagen Therapeutics (VTGN) Receivables (2011 - 2026) Analysis & Trends
Vistagen Therapeutics has reported Receivables for 10 years, with the latest figure at $56000.0 in Q1 2026.
- Quarterly Receivables fell 56.92% year-over-year to $56000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $56000.0 (down 56.92% YoY) and the FY2026 annual result came in at $56000.0, down 56.92% from the prior year.
- Receivables retreated to $56000.0 in Q1 2026 per VTGN's latest filing, from $74000.0 in the prior quarter.
- Over five years, Receivables peaked at $285000.0 in Q1 2023 and troughed at $56000.0 in Q1 2026.
- A 5-year average of $163007.7 and a median of $167000.0 in 2024 frame the typical range for Receivables.
- The sharpest annual moves came in 2022 and 2026: Receivables jumped 146.31% in 2022, then tumbled 56.92% in 2026.
- Over 5 years, Receivables stood at $200000.0 in 2022, then advanced by 11.6% to $223200.0 in 2023, then slumped by 33.24% to $149000.0 in 2024, then plunged by 50.34% to $74000.0 in 2025, then dropped by 24.32% to $56000.0 in 2026.
- According to Business Quant data, Receivables over the past three periods registered $56000.0, $74000.0, and $92000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.57 Bn | 130.72 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 77.99 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 65.00 Bn | 59.82 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 56.27 Bn | 51.13 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 42.00 Bn | 36.90 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 31.60 Bn | 28.29 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 27.68 Bn | 9.29 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.43 Bn | 26.27 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.34 Bn | 26.51 Bn | - | - |
| 10 | Vistagen Therapeutics | 10.49 Mn | 10.49 Mn | - | 37,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 56,000.00 |
| Dec 31, 2025 | 74,000.00 |
| Sep 30, 2025 | 92,000.00 |
| Jun 30, 2025 | 111,000.00 |
| Mar 31, 2025 | 130,000.00 |
| Dec 31, 2024 | 149,000.00 |
| Sep 30, 2024 | 167,000.00 |
| Jun 30, 2024 | 186,000.00 |
| Mar 31, 2024 | 204,000.00 |
| Dec 31, 2023 | 223,200.00 |
| Sep 30, 2023 | 241,900.00 |
| Mar 31, 2023 | 285,000.00 |
| Mar 31, 2022 | 200,000.00 |
| Mar 31, 2021 | 81,200.00 |
| Dec 31, 2016 | 1.25 Mn |
| Mar 31, 2015 | 194,900.00 |
| Mar 31, 2012 | 106,200.00 |
| Dec 31, 2011 | 7,779.00 |
| Sep 30, 2011 | 127,058.00 |
| Jun 30, 2011 | 148,528.00 |